Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Diabetes Research and Clinical Practice|March 22, 2022
Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudyBenjamin N Rao, Nicola Quinn, Andrzej S Januszewski, et al.JAMA|November 9, 2025
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical TrialChristie M Ballantyne, Laura Gellis, Jean-Claude Tardif, et al.Archives of Neurology|June 15, 2011
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialAlfred Callahan, Pierre Amarenco, Larry B Goldstein, et al.Nature Medicine|April 7, 2026
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trialGerald F Watts, Russell Scott, David Sullivan, et al.Lancet (London, England)|October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Evan A Stein, Robert Dufour, et al.Circulation|October 23, 2002
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatinSaskia de Jongh, Leiv Ose, Tamás Szamosi, et al.Nature Medicine|August 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohortsGerald F Watts, Christian Schwabe, Russell Scott, et al.NEJM Evidence|February 6, 2024
RNA Interference Therapy Targeting Apolipoprotein C-III in HypertriglyceridemiaDaniel Gaudet, Peter Clifton, David Sullivan, et al.Diabetes Care|October 8, 2017
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS TrialAbhinav Sharma, Jennifer B Green, Allison Dunning, et al.Journal of Hepatology|December 13, 2022
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitisLung-Yi Mak, Ed Gane, Christian Schwabe, et al.Pageof 5